Cited by 246Cholesterol and Lipid MetabolismCancer, Lipids, and MetabolismSphingolipid Metabolism and Signaling

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index; none of the 26 sources its claims cite is checked for support yet.

Loss of astrocyte cholesterol synthesis disrupts neuronal function and alters whole-body metabolism

Open access

Abstract

Significance: Cholesterol is important for normal brain function and it is believed that astrocytes produce most brain cholesterol. We have previously shown that diabetes results in decreased brain cholesterol synthesis by a reduction in the transcription factor sterol regulatory element-binding protein 2 (SREBP2). Using a mouse model in which SREBP2 has been knocked out in astrocytes, we show that astrocyte SREBP2 is required for normal brain development and behavior. Furthermore, this results in a shift in metabolism driven by increased brain glucose oxidation. Thus, SREBP2-mediated cholesterol synthesis in astrocytes plays an important role in brain development and function, and altered brain cholesterol synthesis may contribute to the interaction between diabetes and altered brain function.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

Astrocyte-specific loss of SREBP2-mediated cholesterol synthesis impairs neurite outgrowth, brain development, behavior, and whole-body energy metabolism in mice. The metabolic phenotype includes reduced adiposity and a shift toward carbohydrate oxidation driven by increased brain glucose oxidation.

Key findings

  • Srebf2 knockdown in C6 glioma cells reduced total and cleaved SREBP2 protein by ∼60% and cholesterol content in cells and media by ∼50%; control glia increased GT1-7 neurite length by 46%, whereas Srebf2-knockdown glia increased it by only 15%.
  • G-SB2KO mice had microcephaly with a 28% reduction in brain weight (343 ± 11 mg vs. 478 ± 5 mg in controls, P < 0.001), impaired nest-building (P < 0.05), and memory retention defects (10.2 ± 1.1 vs. 6.2 ± 0.8 wrong turns, P < 0.01); balance-beam crossing time was 2.7 ± 0.4 vs. 1.9 ± 0.1 s (P < 0.05) with more foot slips (2.3 ± 0.7 vs. 0.8 ± 0.2, P < 0.05).
  • At 9 months, male G-SB2KO mice had a 25% reduction in lean mass and 72% reduction in fat mass; visceral fat was reduced 79% and subcutaneous fat 66%.
  • Dark-phase respiratory exchange ratio was higher in G-SB2KO mice (0.92 ± 0.02 vs. 0.81 ± 0.02, P < 0.001), and brain glucose oxidation increased to 96.8 ± 1.1% vs. 91.4 ± 1.0% in controls (P < 0.01), while gastrocnemius muscle oxidation decreased to 29.8 ± 3.1% vs. 58.6 ± 9.5% (P < 0.01).

Methods

  • In vitro: C6 rat glioma cells were stably infected with lentiviral Srebf2 shRNA or scrambled shRNA; GT1-7 hypothalamic cells were cocultured in transwells, and neurite length was measured using ImageJ/NeuronJ.
  • In vivo: astrocyte-specific conditional SREBP2 knockout mice (hGFAP-cre;Srebf2 lox/lox, G-SB2KO) were compared with littermate controls using behavioral tests (nest building, Stone T-maze, balance beam), DXA/necropsy, metabolic cages, high-fat diet, and cold exposure.
  • Hyperinsulinemic clamps with [U-13C]glucose were performed at blood glucose ∼135 mg/dL; tissue glucose oxidation was assessed as the ratio of 13C2 acetyl CoA to 13C3 alanine, reflecting PDH flux relative to CS flux.

Limitations

  • The paper states that some astrocytes do not express Gfap unless activated, some adult neural progenitor cells express Gfap, and GFAP-negative astrocytes could become GFAP-positive with aging or late neurogenesis could produce neurons with Srebp2 KO.
  • The paper states that the reason for increased brain glucose requirement is not clear.
  • Evident from the text: the in vitro work uses C6 glioma and GT1-7 cell lines rather than primary astrocytes/neurons, and neuronal SREBP2 compensation may partially rescue the astrocyte KO, complicating interpretation of the full phenotype.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1073/pnas.1620506114

Cites

0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

48 Own result · 19 Sources not found · 18 Own interpretation · 8 No basis given · 2 Own method

  • It may state two separate claims as one. 26
  • The quote only partly states this claim. 1
  • Probably not a substantial claim. 11
35 of 35
  • The authors state this as an assumption.

    Astrocytes produce most brain cholesterol.

    “The brain synthesizes its own cholesterol, presumably in astrocytes.”
    “Cholesterol is important for normal brain function and it is believed that astrocytes produce most brain cholesterol.”
  • The paper relies on this without support.

    C6 glioma cells are a valid model for astrocytes in the coculture experiments.

    “We cultured GT1-7 mouse hypothalamic cells with C6 rat glioma cells in transwell plates that allow the cells to share nutrients through the media without making physical contact.”
  • The paper relies on this without support.

    hGFAP-cre specifically targets astrocytes and not other cell types.

    “we created an astrocyte-specific conditional knockout of SREBP2 by breeding mice expressing hGFAP-cre with mice in which the Srebf2 gene contained lox sites on either side of exon 1.”
  • The paper relies on this without support.

    An increase in RER reflects a shift in substrate oxidation toward carbohydrates.

    “This shift in substrate oxidation toward carbohydrates in fed G-SB2KO mice was observed in younger female mice and was confirmed in 9-mo-old male mice as well (Fig. S7B).”
  • The paper relies on this without support.

    Cholesterol is the key mediator of the effect of glial cells on neurite outgrowth.

    “consistent with the important factor being cholesterol.”
  • The paper relies on this without support.

    The brain is a near obligate user of carbohydrates for fuel.

    “which is already a near obligate user of carbohydrates for fuel.”
  • The paper relies on this without support.

    Cholesterol does not significantly cross the blood-brain barrier.

    “however, cholesterol does not significantly cross the blood-brain barrier”
7 of 7

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 47 references

Cited by

Sorted by citations

See all 246

Metadata

Authors
Ferris, H. A., Perry, R. J., Moreira, G. V., Shulman, G. I., Horton, J. D., & Kahn, C. R.
Affiliations
  • Joslin Diabetes Center (US)
  • Yale University (US)
  • Howard Hughes Medical Institute (US)
  • The University of Texas Southwestern Medical Center (US)
Venue
Proceedings of the National Academy of Sciences
Published
2017-01-17
Volume
114
Issue
5
Pages
1189-1194
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2579178448
Cited by
246
References
43
Citations by year
2026: 26 · 2025: 38 · 2024: 34 · 2023: 37 · 2022: 29 · 2021: 25 · 2020: 29 · 2019: 19 · 2018: 5 · 2017: 4
FWCI
15.97
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (5K08DK097293, R01 DK-40936, MMPC DK059635, R37DK031036)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
Keywords
SREBP2, brain cholesterol, astrocyte-neuron co-culture, neurite outgrowth, brain development, motor defects, energy balance, body composition, glucose oxidation, brain metabolism, diabetes mellitus, metabolic disorders
MeSH terms
Animals, Astrocytes, Body Composition, Brain, Cholesterol, Energy Metabolism, Female, Glioma, Glucose, Hyperinsulinism, Male, Mice, Inbred C57BL, Neoplasm Proteins, Nesting Behavior, Oxidation-Reduction, Neurites, Mice, Knockout, Maze Learning, Rotarod Performance Test, Cell Line, Tumor, Mice, Rats, Sterol Regulatory Element Binding Proteins, Sterol Regulatory Element Binding Protein 2, Gene Knockdown Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review